253 related articles for article (PubMed ID: 31563447)
1. Towards the understanding of the UV light, riboflavin and additive solution contributions to the in vitro lesions observed in Mirasol®-treated platelets.
Abonnenc M; Crettaz D; Sonego G; Escolar G; Tissot JD; Prudent M
Transfus Clin Biol; 2019 Nov; 26(4):209-216. PubMed ID: 31563447
[TBL] [Abstract][Full Text] [Related]
2. Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?
van der Meer PF; Bontekoe IJ; Daal BB; de Korte D
Transfusion; 2015 Aug; 55(8):1900-8. PubMed ID: 25752624
[TBL] [Abstract][Full Text] [Related]
3. Riboflavin and ultraviolet light for pathogen reduction of murine cytomegalovirus in blood products.
Keil SD; Saakadze N; Bowen R; Newman JL; Karatela S; Gordy P; Marschner S; Roback J; Hillyer CD
Transfusion; 2015 Apr; 55(4):858-63. PubMed ID: 25438832
[TBL] [Abstract][Full Text] [Related]
4. Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling.
Reid S; Johnson L; Woodland N; Marks DC
Transfusion; 2012 Oct; 52(10):2094-103. PubMed ID: 22320126
[TBL] [Abstract][Full Text] [Related]
5. Pathogen reduction technology (Mirasol) treated single-donor platelets resuspended in a mixture of autologous plasma and PAS.
Janetzko K; Hinz K; Marschner S; Goodrich R; Klüter H
Vox Sang; 2009 Oct; 97(3):234-9. PubMed ID: 19790298
[TBL] [Abstract][Full Text] [Related]
6. [Effects of use of riboflavin and ultraviolet light for pathogen inactivation on quality of platelet concentrates].
Stanojković Z; Antić A; Stojanović M
Vojnosanit Pregl; 2011 Jun; 68(6):489-94. PubMed ID: 21818915
[TBL] [Abstract][Full Text] [Related]
7. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro.
Zeddies S; De Cuyper IM; van der Meer PF; Daal BB; de Korte D; Gutiérrez L; Thijssen-Timmer DC
Transfusion; 2014 Sep; 54(9):2292-300. PubMed ID: 24689812
[TBL] [Abstract][Full Text] [Related]
8. In vitro characteristics and in vivo platelet quality of whole blood treated with riboflavin and UVA/UVB light and stored for 24 hours at room temperature.
Lunde THF; Hartson L; Bailey SL; Hervig TA
Transfusion; 2021 Jul; 61 Suppl 1():S101-S110. PubMed ID: 34269459
[TBL] [Abstract][Full Text] [Related]
9. Functional characteristics and clinical effectiveness of platelet concentrates treated with riboflavin and ultraviolet light in plasma and in platelet additive solution.
Ignatova AA; Karpova OV; Trakhtman PE; Rumiantsev SA; Panteleev MA
Vox Sang; 2016 Apr; 110(3):244-52. PubMed ID: 26646605
[TBL] [Abstract][Full Text] [Related]
10. In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology.
Ostrowski SR; Bochsen L; Salado-Jimena JA; Ullum H; Reynaerts I; Goodrich RP; Johansson PI
Transfusion; 2010 Oct; 50(10):2210-9. PubMed ID: 20456708
[TBL] [Abstract][Full Text] [Related]
11. Proteomic analysis of extracellular vesicles derived from platelet concentrates treated with Mirasol® identifies biomarkers of platelet storage lesion.
Hermida-Nogueira L; Barrachina MN; Izquierdo I; García-Vence M; Lacerenza S; Bravo S; Castrillo A; García Á
J Proteomics; 2020 Jan; 210():103529. PubMed ID: 31605789
[TBL] [Abstract][Full Text] [Related]
12. The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution.
Reikvam H; Marschner S; Apelseth TO; Goodrich R; Hervig T
Blood Transfus; 2010 Jul; 8(3):186-92. PubMed ID: 20671879
[TBL] [Abstract][Full Text] [Related]
13. Quality control of riboflavin-treated platelet concentrates using Mirasol® PRT system: Polish experience.
Lachert E; Kubis J; Antoniewicz-Papis J; Rosiek A; Woźniak J; Piotrowski D; Przybylska Z; Mikołowska A; Marschner S; Łętowska M
Adv Clin Exp Med; 2018 Jun; 27(6):765-772. PubMed ID: 29877637
[TBL] [Abstract][Full Text] [Related]
14. Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution.
Picker SM; Tauszig ME; Gathof BS
Transfusion; 2012 Mar; 52(3):510-6. PubMed ID: 21981030
[TBL] [Abstract][Full Text] [Related]
15. Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology.
Ostrowski SR; Bochsen L; Windeløv NA; Salado-Jimena JA; Reynaerts I; Goodrich RP; Johansson PI
Transfusion; 2011 Feb; 51(2):344-56. PubMed ID: 20723169
[TBL] [Abstract][Full Text] [Related]
16. Human platelets pathogen reduced with riboflavin and ultraviolet light do not cause acute lung injury in a two-event SCID mouse model.
Chi X; Zhi L; Vostal JG
Transfusion; 2014 Jan; 54(1):74-85. PubMed ID: 23656563
[TBL] [Abstract][Full Text] [Related]
17. In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin/UVB-treated platelet concentrates.
Abonnenc M; Sonego G; Crettaz D; Aliotta A; Prudent M; Tissot JD; Lion N
Transfusion; 2015 Sep; 55(9):2219-30. PubMed ID: 25873361
[TBL] [Abstract][Full Text] [Related]
18. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover.
Johnson L; Winter KM; Reid S; Hartkopf-Theis T; Marschner S; Goodrich RP; Marks DC
Vox Sang; 2011 Oct; 101(3):208-14. PubMed ID: 21492184
[TBL] [Abstract][Full Text] [Related]
19. Irreversible oxidations of platelet proteins after riboflavin-UVB pathogen inactivation.
Sonego G; Abonnenc M; Crettaz D; Lion N; Tissot JD; Prudent M
Transfus Clin Biol; 2020 Feb; 27(1):36-42. PubMed ID: 30638959
[TBL] [Abstract][Full Text] [Related]
20. Real-time measurement of platelet shape change by light scattering under riboflavin and ultraviolet light treatment.
Terada C; Shiba M; Satake M; Tadokoro K
Transfusion; 2016 Mar; 56(3):587-95. PubMed ID: 26536611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
